Deflazacort Use in Duchenne Muscular Dystrophy: An 8-Year Follow-Up

Pediatric Neurology

Volumn 38, Issue 3, 2008, Pages 200-206

  Houde, Sylvie ^a   Filiatrault, Michèle ^a   Fournier, Anne ^a,b   Dubé, Julie ^a   D'Arcy, Sylvie ^a   Bérubé, Denis ^b   Brousseau, Yves ^a   Lapierre, Guy ^a,b   Vanasse, Michel ^b  

^a Marie Enfant Rehabilitation Center   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DEFLAZACORT; PAMIDRONIC ACID;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; CATARACT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; FOLLOW UP; HEART EJECTION FRACTION; HEART FUNCTION; HUMAN; LIMB FRACTURE; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; SCOLIOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VERTEBRA FRACTURE; VITAL CAPACITY; WALKING; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; CATARACT; FRACTURES, BONE; HUMANS; LONGITUDINAL STUDIES; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PREGNENEDIONES; SCOLIOSIS; TREATMENT OUTCOME;

EID: 38949092529     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2007.11.001     Document Type: Article

References (33)

1. Brooke M.H. A randomized trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. [Abstract]. Neurology 46 Suppl 1 (1996) A476
2. Mesa L.E., Dubrovsky A.L., Corderi J., Marco P., and Flores D. Steroids in Duchenne muscular dystrophy: deflazacort trial. Neuromuscul Disord 1 (1991) 261-266
3. Fenichel G.M., Mendell J.R., Moxley III R.T., et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 48 (1991) 575-579
4. Fenichel G.M., Florence J.M., Pestronk A., et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 41 (1991) 1874-1877
5. Sansome A., Royston P., and Dubowitz V. Steroids in Duchenne muscular dystrophy: pilot study of a new low-dosage schedule. Neuromuscul Disord 3 (1993) 567-569
6. Griggs R.C., Moxley III R.T., Mendell J.R., et al. Duchenne dystrophy: Randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 43 (1993) 520-527
7. Reitter B. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain Dev 17 Suppl (1995) 39-43
8. Angelini C., Pegoraro E., Turella E., Intino M.T., Pini A., and Costa C. Deflazacort in Duchenne dystrophy: study of long-term effect. [Erratum in: Muscle Nerve 1994;17:833]. Muscle Nerve 17 (1994) 386-391
9. Carter G.T., and McDonald C.M. Preserving function in Duchenne dystrophy with long-term pulse prednisone therapy. Am J Phys Med Rehabil 79 (2000) 455-458
10. Biggar W.D., Gingras M., Fehlings D.L., Harris V.A., and Steele C.A. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 138 (2001) 45-50
11. Bonifati M.D., Ruzza G., Bonometto P., et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 23 (2000) 1344-1347
12. Schara U., Mortier J., and Mortier W. Long-term steroid therapy in Duchenne muscular dystrophy: positive results versus side effects. J Clin Neuromuscul Dis 2 (2001) 179-183
13. Wong B., and Christopher C. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. J Child Neurol 17 (2002) 183-190
14. Dubowitz V., Kinali M., Main M., Mercuri E., and Muntoni F. Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy. Eur J Paediatr Neurol 6 (2002) 153-159
15. Connolly A.M., Schierbecker J., Renna R., and Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 12 (2002) 917-925
16. Biggar W.D., Politano L., Harris V.A., et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord 14 (2004) 476-482
17. Dubowitz V. 75th European Neuromuscular Centre International Workshop: 2nd workshop on the treatment of muscular dystrophy, 10-12 December, 1999, Naarden, The Netherlands. Neuromuscul Disord 10 (2000) 313-320
18. Biggar W.D., Harris V.A., Eliasoph L., and Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16 (2006) 249-255
19. Markham L.W., Spicer R.L., Khoury P.R., Wong B.L., Mathews K.D., and Cripe L.H. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 26 (2005) 768-771
20. Jefferies J.L., Eidem B.W., Belmont J.W., et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 112 (2005) 2799-2804
21. Alman B.A., Raza S.N., and Biggar W.D. Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. J Bone Joint Surg Am 86-A (2004) 519-524
22. Polgar G., and Promadhat V. Standard values. Pulmonary function testing in children: techniques and standards (1971), W.B. Saunders, Philadelphia 102-103
23. Muntoni F., Bushby K., and Manzur A.Y. Muscular Dystrophy Campaign Funded Workshop on Management of Scoliosis in Duchenne Muscular Dystrophy, 24 January 2005, London, UK. Neuromuscul Disord 16 (2006) 210-219
24. Balaban B., Matthews D.J., Clayton G., and Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 84 (2005) 843-850
25. Silversides C.K., Webb G.D., Harris V.A., and Biggar W.D. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 91 (2003) 769-772
26. McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases: Duchenne muscular dystrophy. Am J Phys Med Rehabil 74 5 Suppl (1995) S70-S92
27. Hawker G.A., Ridout R., Harris V.A., Chase C.C., Fielding L.J., and Biggar W.D. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchenne's muscular dystrophy. Arch Phys Med Rehabil 86 (2005) 284-288
28. Rapaport D., Colletto G.M., Vainzof M., Duaik M.C., and Zatz M. Short stature in Duchenne muscular dystrophy. Growth Regul 1 (1991) 11-15
29. Larson C.M., and Henderson R.C. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop 20 (2000) 71-74
30. Bianchi M.L., Mazzanti A., Galbiati E., et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int 14 (2003) 761-767
31. Vestergaard P., Glerup H., Steffensen B.F., Rejnmark L., Rahbek J., and Mosekilde L. Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. J Rehabil Med 33 (2001) 150-155
32. McDonald D.G.M., Kinali M., Gallagher A.C., et al. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol 44 (2002) 695-698
33. Talim B., Malaguti C., Gnudi S., Politano L., and Merlini L. Vertebral compression in Duchenne muscular dystrophy following deflazacort. Neuromuscul Disord 12 (2002) 294-295